Straightforward convergent access to 2-arylated polysubstituted benzothiazoles

Omar Sadek,1,2 David M. Perrin,2 Emmanuel Gras*1,3

Addresses:
1) LCC, CNRS UPR 8241, Université de Toulouse, UPS, INPT, 205 route de Narbonne 31077 Toulouse Cedex 4
2) Chemistry Department, 2036 Main Mall, UBC, Vancouver, BC, V6T 1Z1, Canada
3) ITAV, CNRS USR 3505, Université de Toulouse, UPS, 1 place Pierre Potier, 31106 Toulouse Cedex 1

Email : Emmanuel Gras - emmanuel.gras@lcc-toulouse.fr

Abstract:

A modular access to 2,4 disubstituted benzothiazoles has been achieved though the intermediacy of 4-bromo-2-iodobenzothiazole. The difference in reactivity of both halogens was advantageously exploited to achieve sequential Suzuki-Miyaura cross-coupling giving access to a range of polyaromatic derivatives featuring a central benzothiazole core.

Keywords:
Orthogonal Suzuki-Miyaura cross coupling; benzothiazole; boronic derivatives.

Introduction

The benzothiazole core is considered a privileged fused bicyclic heterocycle in light of its applications in pharmaceutical, agrochemical, and materials chemistry.[1-3] This has driven the development of increasingly efficient methodologies towards the synthesis of functionalised 2-arylated benzothiazole scaffolds.[4-6] More recently, these scaffolds have found applications in organocatalyzed (de)hydro-silylation reactions where they function as carbon-centred Lewis acids in the activation of Si–H σ bonds.[7] Substituted
benzothiazoles are also involved in important applications in organic light-emitting devices (OLEDs).\cite{8-10} Similar to other benzazoles,\cite{11-14} they quite commonly exhibit interesting photochemical properties including processes such as Excited State Intramolecular Proton Transfer (ESIPT).\cite{15, 16} These molecules have also been intensively studied for their dual action potential as metal chelators and as intercalating compounds targeting pathological peptidic aggregates that of interest for imaging various dementias e.g. Alzheimer's Disease.\cite{17, 18}

Figure 1: Benzothiazole scaffolds integrated into various applications

Considering that the nitrogen atom of the benzothiazole is key in all the applications mentioned and illustrated above, we focused our attention on modulating its environment by introducing substituents on position 2 and 4 of the benzothiazole core in a convergent fashion. Although numerous strategies have been designed to access substituted benzothiazoles, in nearly all cases, strategies have required non-versatile and non-modular syntheses.\cite{1} One major path relies on the cyclisation of functionalised arylthioamides or arylthioureas. Such starting materials require time-consuming
methods to generate thioamides (or thioureas) prior to cyclisation, most commonly from the corresponding amide with Lawesson’s reagent. Alternatively, benzothiazoles can also be accessed by condensing aldehydes with 2-aminothiophenols in the presence of an oxidant (air being the mildest) or reaction with activated esters and/or acid halides. However, drawbacks with these approaches are readily appreciated by considering the poor shelf-life of many aldehydes, the high-reactivity of acid halides, as well as the poor availability of functionalized 2-aminothiophenols, which are themselves air-sensitive and easily decomposed.

A more facile and highly convergent approach, based on readily-available and stable building blocks, would be to leverage the extensive portfolio of boronic acids to access polysubstituted benzothiazole derivatives through Suzuki-Miyaura cross coupling starting with a suitable 2-iodobenzothioazole as a readily accessed coupling partner. Moreover, taking advantage of the C-2 activated position of the heterocycle might prove sufficiently selective for orthogonal coupling thus providing diversely polysubstituted benzothiazoles in a highly convergent and straightforward fashion. Herein, we present a preliminary report that establishes this strategy as a viable route to polysubstituted benzothiazoles. To test this hypothesis, we envisioned a practical and convergent strategy involving 4-bromo-2-iodobenzothiazole 3 (Scheme 1) as a key intermediate that would enable regio/chemoselective coupling to deliver a series of C2/C4 arylated benzothiazoles. This strategy is attractive as it is highly modular as it allows for considerable synthetic versatility considering the expansive library of aryl boronic acids and derivatives available, both commercially and synthetically, as suitable coupling partners.\[19, 20\] Herein, we describe the swift synthesis of versatile intermediate 3,
substituted with two different halogens that, as part of our design, demonstrates efficient access to the said benzothiazoles via chemoselective and regioselective functionalisation with various aromatic substituents.

**Results and Discussion**

**Synthesis of di-halogenated intermediate**

We sought a simple, efficient, and high-yielding synthetic route with an eye to utilizing affordable and common laboratory reagents. Starting from commercially-available 2-bromoaniline, thiourea 1 was obtained following standard protocol.\(^{[21, 22]}\) Subsequent Hugershoff cyclization with Br\(_2\) yielded the desired 2-amino-4-bromobenzothiazole (2) in excellent yield.\(^{[23, 24]}\) One-pot iodination of 2, under Sandmeyer conditions, provided 4-bromo-2-iodobenzothiazole (3) in excellent yield (Scheme 1). Key intermediate 3 is obtained in three synthetic steps in 63% global yield without further optimization. This represents a significant improvement over the 5-step approach from the less available 2,3-dibromoaniline as reported in patent literature.\(^{[25]}\)

![Scheme 1 Synthesis of 4-bromo-2-iodobenzothiazole. a, BzCl, NH\(_4\)SCN, acetone, reflux, 1 hour. b, Br\(_2\), CHCl\(_3\), reflux 1.5 hours. c, (i) p-TsOH·H\(_2\)O, MeCN, room temperature, (ii) t-BuONO, -5 °C, 30 minutes, (iii) KI, cat. Cul, H\(_2\)O, 0 °C then room temperature, 18 h.](image)

**Functionalisation of key benzothiazole intermediate**

Given the well-established reactivity differences between C(sp\(^2\))-I and C(sp\(^2\))-Br bonds with respect to oxidative addition at a transition metal centre, 3 should submit to
chemoselective and regioselective Suzuki-Miyaura cross-coupling with various aryl boron derivatives (Scheme 2). Indeed, products of selective mono-arylation of 3 were obtained by initial cross-coupling at C-2, at moderate reaction temperature (90 °C), selective arylation could be achieved while safeguarding the C-Br bond intact for further functionalization (vide infra). Notably, 2-hydroxyphenyl-boronic acid, 2-aminophenylboronic acid, and N-Boc-indole-2-boronic acid could be coupled to 3, furnishing 2-aryl-4-bromobenzothiazoles 4, 5 and 6, respectively in good yields. Notably, if desired, one-pot, double cross-coupling with 2-aminophenylboronic acid was found to be highly efficient, providing the corresponding 2,4-dianiline (7) in 87% yield.

To capitalize on the extant C-Br bond, compounds 4, 6, and 10 could be further functionalised in step-wise fashion, at C-4, via cross-coupling with various arylboronic acids or trifluoroborates. For example, reaction of 4 with potassium N-Boc-indole-2-trifluoroborate, under conditions reported by Molander et al.,[26] or with 2-aminophenylboronic acid furnished 2,4-diarylbenzothiazoles 8 and 9, respectively, in good yields. The aniline in benzothiazole 5 was shown to undergo mono-N-methylation, while conserving the C-Br bond,[27] in good yield to provide 10, which was further cross-coupled with 2-hydroxyphenylboronic acid to furnish 2,4-diarylbenzothiazole 11. Finally, 4-bromo-2-indolebenzothiazole 6, after Boc-deprotection of 6 to 6a, could be coupled with 2-hydroxyphenylboronic acid to provide 12 in high yield.
Scheme 2. Transformation of 3 into various 2- and 2,4-disubstituted benzothiazoles. a, 2-hydroxyphenylboronic acid, Pd(PPh₃)₄, Na₂CO₃, DMF/H₂O, microwave, 90 °C, 1 hour. b, 2-aminophenylboronic acid, Pd(PPh₃)₄, XantPhos, Na₂CO₃, 1,4-dioxane/H₂O, microwave, 90 °C, 1 hour. c, N-Boc-indole-2-boronic acid, Pd(PPh₃)₄, Cs₂CO₃, 1,4-dioxane/H₂O, microwave, 90 °C, 1 hour. d, 2-aminophenylboronic acid, Pd(PPh₃)₄, Na₂CO₃, DMF/H₂O, microwave, 120 °C, 5 hours. e, potassium N-Boc-indole-2-trifluoroborate, Pd(Oac)₂, SPhos, Na₂CO₃, EtOH, 85 °C, 5 hours. f, 2-aminophenylboronic acid, Pd(PPh₃)₄, Na₂CO₃, DMF/H₂O, microwave, 120 °C, 1 hour. g, Re(NH(CH₂CH₂PPh₂)₂)(CO)₃Br, Cs₂CO₃, MeOH, 140 °C, 5 days. h, 2-hydroxyphenylboronic acid, Pd(PPh₃)₄, Na₂CO₃, DMF/H₂O, 120 °C, 18 hours. i, TFA/DCM (1:1), room temperature, 2 hours. j, 2-hydroxyphenylboronic acid, Pd(PPh₃)₄, Na₂CO₃, DMF/H₂O, 120 °C, 1 hour.

Photophysical Properties

Given the increasing interest and application of the absorptive and emissive properties of benzothiazoles, we briefly studied the photophysical properties of these novel benzothiazoles. As a general trend, these benzothiazoles exhibit similar absorption spectra, consisting of large bands in the UV region of the spectrum; they absorb strongly with absorption maxima ranging from 339 to 405 nm that are attributed to characteristic π-π* transitions. However, on closer inspection it becomes evident that the nature of the aromatic group at C-2 determines the absorption profile, while the
substitution at C-4 delivers fine-tuning of the absorption maximum (Figure 2). These compounds were also found to be fluorescent, with broad emission bands ranging from 403 to 519 nm, corresponding to Stoke shifts ($\Delta$ss) varying from 39 to 180 nm. The large $\Delta$ss are only observed for compounds 4, 8 and 9 which feature 2-hydroxyphenyl at C-2, allowing for the possibility of ESIPT which induces significant structural reorganisation in the excited state, accounting for the large $\Delta$ss. In contrast to the relationship observed in absorption, the substituent at C-4 has no effect on emission profiles or maxima.

Figure 2: UV Absorption spectra of 4, 8 and 9.
Figure 2: UV Absorption spectra of 12 and 6a.

Figure 2: UV Absorption spectra of 5, 7, 10 and 11.
Figure 2: Fluorescence spectra of 4, 5, 6a, 7, 8, 9, 10, 11 and 12.

Table 1 Photophysical properties of compounds 4-12

| Compound | $\lambda_{\text{abs}}$ (nm) | $\log \epsilon$ (M$^{-1}$ cm$^{-1}$) | $\lambda_{\text{em}}$ (nm) | $\Delta_{\text{ss}}$ (nm · cm$^{-1}$) |
|----------|-----------------------------|--------------------------------------|-----------------------------|---------------------------------------|
| 4        | 339                         | 4.1                                  | 519                         | 180 - 10231                           |
| 5        | 376                         | 4.0                                  | 442                         | 66 - 3971                             |
| 6a       | 368                         | 4.4                                  | 407                         | 39 - 2604                             |
| 7        | 373                         | 4.0                                  | 438                         | 65 - 3979                             |
| 8        | 351                         | 4.1                                  | 506                         | 155 - 8727                            |
| 9        | 339                         | 4.2                                  | 513                         | 174 - 10005                           |
| 10       | 405                         | 4.1                                  | 466                         | 61 - 3232                             |
| 11       | 405                         | 3.6                                  | 471                         | 66 - 3460                             |
| 12       | 360                         | 4.5                                  | 403                         | 43 - 2964                             |
Conclusion

In conclusion, here we have demonstrated the facile synthesis of a wide variety of 2-aryl-4-bromo and 2,4-diarylbenzothiazole derivatives via selective Suzuki-Miyaura cross-coupling with key benzothiazole intermediate 3. This scaffold has proven versatile, allowing selective structural elaboration firstly at the C-2 position, in high yields, followed by functionalisation at the C-4 position; the scaffold can also be di-functionalised in one-pot at both the C-2 and C-4 positions. This strategy gives rapid access to a diverse family of benzothiazoles with tuneable photophysical properties. Although our synthesis is somewhat limited in scope, we have demonstrated that this reaction manifold is readily amenable to preparing a large number of tricyclic compounds starting with (hetero)arylboronic acids. Hence, in this preliminary report, we acknowledge this methodology serves as a proof of concept for its expansion towards the functionalisation of other positions on the benzothiazole core in a similar fashion. It is readily anticipated more densely functionalized bromoanilines will readily submit to this reaction scheme. The novel benzothiazoles derivatives reported here accessible through 3, or derivatives thereof, are further anticipated to be of interest for photophysical studies in both solution and the solid-state, as well as their investigation as Lewis acid catalysts and as chelators for various metal cations. Studies towards these goals are currently underway.

Supporting Information

Supporting information including extensive experimental details and compounds characterizations (IR, $^1$H and $^{13}$C NMR, HRMS) are provided.
ORCID iDs

Omar Sadek – 0000-0003-1853-541X

David M. Perrin – 0000-0001-8342-6346

Emmanuel Gras – 0000-0002-1178-3579

Acknowledgements

Financial support from the Université de Toulouse III-Paul Sabatier (Ph.D. Funding O.S.), French Canadian Research Fund, and Centre National de la Recherche Scientifique (CNRS) is gratefully acknowledged. Procedures provided in the supplementary information are related to the PhD Thesis of Omar Sadek “Exploiting boron-fluorine bonds for fluorination and synthesis of potential bi-modal imaging agents.” Coordination chemistry. Université Paul Sabatier - Toulouse III; University of British Columbia. Library, 2018. English.

References

1. Keri, R. S.; Patil, M. R.; Patil, S. A.; Budagumpi, S., *Eur. J. Med. Chem.* **2015**, *89*, 207-251.
2. Gill, R. K.; Rawal, R. K.; Bariwal, J., *Arch. Pharm.* **2015**, *348*, 155-178.
3. Le Bozec, L.; Moody, C. J., *Aust. J. Chem.* **2009**, *62*, 639-647.
4. Prajapati, N. P.; Vekariya, R. H.; Borad, M. A.; Patel, H. D., *RSC Adv.* **2014**, *4*, 60176-60208.
5. Dadmal, T. L.; Katre, S. D.; Mandewale, M. C.; Kumbhare, R. M., *New J. Chem.* **2018**, *42*, 776-797.
6. Noël, S.; Cadet, S.; Gras, E.; Hureau, C., *Chem. Soc. Rev.* **2013**, *42*, 7747.
7. Fasano, V.; Radcliffe, J. E.; Curless, L. D.; Ingleson, M. J., *Chem. Eur. J.* **2017**, *23*, 187-193.
8. Wang, B.; Liang, F.; Hu, H.; Liu, Y.; Kang, Z.; Liao, L.-S.; Fan, J., *J. Mater. Chem. C* **2015**, *3*, 8212-8218.
9. Mabrouk, A.; Azazi, A.; Alimi, K., *J. Phys. Chem. Solids* **2010**, *71*, 1225-1235.
10. Duarte, L.; Germino, J. C.; Berbigier, J. F.; Barboza, C. A.; Faleiros, M. M.; de Alencar Simoni, D.; Galante, M. T.; de Holanda, M. S.; Rodembusch, F. S.; Atvars, T. D. Z., *Phys. Chem. Chem. Phys.* 2019, 21, 1172-1182.
11. Heyer, E.; Benelhadj, K.; Budzák, S.; Jacquemin, D.; Massue, J.; Ulrich, G., *Chem. Eur. J.* 2017, 23, 7324-7336.
12. Felouat, A.; Curtil, M.; Massue, J.; Ulrich, G., *New J. Chem.* 2019, 43, 9162-9169.
13. Massue, J.; Pariat, T.; P, M. V.; Jacquemin, D.; Durko, M.; Chotouki, T.; Szmitko, L.; Mysiwiec, J.; Ulrich, G., *Nanomaterials* 2019, 9.
14. Munch, M.; Curtil, M.; Vérité, P. M.; Jacquemin, D.; Massue, J.; Ulrich, G., *Eur. J. Org. Chem.* 2019, 2019, 1134-1144.
15. Gao, T.; Xu, P.; Liu, M.; Bi, A.; Hu, P.; Ye, B.; Wang, W.; Zeng, W., *Chem. Asian J.* 2015, 10, 1142-1145.
16. Xu, P.; Gao, T.; Liu, M.; Zhang, H.; Zeng, W., *Analyst* 2015, 140, 1814-1816.
17. Rodríguez-Rodríguez, C.; Sánchez de Groot, N.; Rimola, A.; Álvarez-Larena, A. n.; Lloveras, V.; Vidal-Gancedo, J.; Ventura, S.; Vendrell, J.; Sodupe, M.; González-Duarte, P., *J. Am. Chem. Soc.* 2009, 131, 1436-1451.
18. Rodríguez-Rodríguez, C.; Telpoukhovskaia, M. A.; Alí-Torres, J.; Rodríguez-Santiago, L.; Manso, Y.; Bailey, G. A.; Hidalgo, J.; Sodupe, M.; Orvig, C., *Metallooms* 2015, 7, 83-92.
19. Molander, G. A., *J. Org. Chem.* 2015, 80, 7837-7848.
20. Lennox, A. J. J.; Lloyd-Jones, G. C., *Chem. Soc. Rev.* 2014, 43, 412-443.
21. Rasmussen, C. R.; Villani Jr, F. J.; Weaver, L. E.; Reynolds, B. E.; Hood, A. R.; Hecker, L. R.; Nortey, S. O.; Hanslin, A.; Costanzo, M. J.; Powell, E. T.; Molinari, A. J.; Villani, J., F. J.; Weaver, L. E.; Reynolds, B. E.; Hood, A. R.; Hecker, L. R.; Nortey, S. O.; Hanslin, A.; Costanzo, M. J.; Powell, E. T.; Molinari, A. J., *Synthesis* 1988, 1988, 456-459.
22. Thanigaimalai, P.; Le Hoang, T. A.; Lee, K. C.; Bang, S. C.; Sharma, V. K.; Yun, C. Y.; Roh, E.; Hwang, B. Y.; Kim, Y.; Jung, S. H., *Bioorg. Med. Chem. Lett.* 2010, 20, 2991-2993.
23. Hugershoff, A., *Ber. Dtsch. Chem. Ges.* 1901, 34, 3130-3135.
24. Hugershoff, A., *Ber. Dtsch. Chem. Ges.* 1903, 36, 3121-3134.
25. Steining, A. G.; Mulvihill, M. J.; Wang, J.; Werner, D. S.; Weng, Q.; Kan, J.; Coate, H.; Chen, X. 2-aminopyridine kinase inhibitors. U.S. Patent 0197862, Aug. 6, 2009
26. Molander, G. A.; Canturk, B.; Kennedy, L. E., *J. Org. Chem.* 2009, 74, 973-980.
27. Wei, D.; Sadek, O.; Dorcet, V.; Roisnel, T.; Darcel, C.; Gras, E.; Clot, E.; Sortais, J.-b., *J. Catal.* 2018, 366, 300-309.